Hizentra CIDP denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits the Quantity of Hizentra for CIDP — and How to Appeal

Humana's quantity-limit denial for Hizentra (subcutaneous immune globulin) in chronic inflammatory demyelinating polyneuropathy (CIDP) typically means the plan has approved the drug in principle but capped the amount dispensed per fill or per month. Because Hizentra dosing is individualized — the prescriber calculates the correct amount based on the patient's body weight and clinical response — a blanket quantity ceiling can leave patients undertreated.

### Why This Denial Is Appealable

Quantity limits must be medically justified. If the prescriber has determined, based on clinical assessment and the FDA-approved prescribing information for Hizentra, that a patient requires an amount above Humana's default limit, the plan is obligated to consider that medical judgment. Denying a medically necessary quantity without reviewing the individual patient's needs may violate the plan's own coverage criteria and federal parity standards.

### Federal Appeal Rights

• Internal appeal: File within the timeframe shown on the denial notice (typically 180 days for ACA plans). Humana must respond within 30 days for non-urgent requests.
• External review: Under ACA §2719, you have the right to independent external review after exhausting internal appeals — generally within four months of the final internal denial. ERISA §503 guarantees a full-and-fair review for employer plans.
• Expedited review: If the standard timeline would seriously jeopardize your health, request expedited review — decisions are typically required within 72 hours.

### Documentation to Gather

1. Confirmed CIDP diagnosis: Neurology or specialist notes establishing the diagnosis, including electrodiagnostic findings and clinical severity assessment. 2. Current treatment history: Records of prior IVIG or SCIG therapy, including dates, response, and dose adjustments made by the prescriber. 3. Prescriber medical-necessity letter: A letter from the treating neurologist explaining why the specific quantity ordered — calculated per the FDA-approved Hizentra label — is required for this patient, and why the plan's default limit is clinically inadequate. 4. Body-weight documentation: Current weight from the chart, so the reviewer can confirm the ordered quantity is consistent with label-directed dosing calculations. 5. Functional severity documentation: Chart notes describing disability, relapse risk, or functional decline that would result from under-dosing.

### Criteria-Mapping Structure

Copy each requirement listed in Humana's published medical/coverage policy for Hizentra or subcutaneous immunoglobulin, then pair each requirement with the specific chart fact that satisfies it. Common requirements include confirmed CIDP diagnosis, documented inadequate response to or intolerance of alternatives, and quantity calculated per label. Answer each criterion explicitly; do not leave any unanswered. Attach the relevant chart pages behind each answer.

Consult the FDA-approved Hizentra prescribing label and Humana's current Hizentra coverage policy for the exact eligibility thresholds and quantity parameters that apply to your plan year.